



**REGION 11
CHICAGO EMS SYSTEM
MEDICATION TABLE**

Medication Name: Atropine – Nerve Agent & Organophosphate Poisoning

Approved: EMS Medical Directors Consortium

Effective: August 1, 2022

GENERIC NAME	Atropine: Nerve Agent and Organophosphate Poisoning
TRADE NAME	Atropine, AtroPen, component of Mark 1 Kits and DuoDote
CLASSIFICATION	Anticholinergic, antidote for organophosphate and nerve agent poisoning
DOSAGE FORMS	<ul style="list-style-type: none"> • Chempak atropine: 0.4mg/ml (20 mg vial) • Duodote: 2 mg atropine • Mark 1 Kit: 2 mg atropine
ACTION(S)	<ul style="list-style-type: none"> • Competitively inhibits action of acetylcholine at muscarinic receptor sites. Receptors affected include salivary, bronchial, sweat glands, eyes, heart and GI tract (most-to-least sensitive) • Increases SA and AV node conduction • Dries secretions
INDICATIONS	For the management of toxicity caused by organophosphate insecticides and nerve agents poisoning (e.g. tabun, sarin, soman) including muscle fasciculations, nausea and vomiting, copious secretions, bradycardia, weakness, shortness of breath, unconsciousness, convulsions, paralysis and apnea
CONTRAINDICATIONS	Known or documented hypersensitivity in non-ACLS/nerve agent/organophosphate scenarios
ADULT DOSE / ROUTE	<ul style="list-style-type: none"> • Nerve Agent/Organophosphate Poisoning: 2 mg IM and titrate until desired effect (drying of tracheobronchial secretions, improvement of breathing and bradycardia) • No max dose.
PEDIATRIC DOSE / ROUTE	<ul style="list-style-type: none"> • Pediatric nerve agent/organophosphate exposure dosages are not included in the Medication Table • See Acetylcholinesterase Inhibitors Exposure – BLS/ALS Protocol
SIDE EFFECTS	Decreased secretions/dry mouth, intense facial flushing and hot skin temperature, blurred vision or pupil dilation, photophobia, tachycardia, restlessness